ArticleDiabetes, obesity & metabolism2022

Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Timothy S Bailey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.